Apoptosis is a programmed cell death process that plays a critical role in development and homeostasis. Dysregulation of apoptosis is a hallmark of cancer, as cancer cells often evade apoptosis through various mechanisms. Targeting apoptotic pathways has been a major focus in cancer therapy, with efforts to develop drugs that induce apoptosis in cancer cells. Apoptosis can occur through intrinsic or extrinsic pathways, and these pathways interact with other signaling mechanisms such as p53 and the integrated stress response (ISR). Recent advances in cancer therapy include drugs targeting BCL-2, TRAIL analogs, DR5 antibodies, and strategies targeting p53 and the ISR. Venetoclax, a BCL-2 inhibitor, has been approved by the FDA for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). TRAIL analogs and DR5 agonist antibodies have also been developed, but their clinical efficacy has been limited due to issues such as short half-life and poor receptor clustering. TLY012, a second-generation TRAIL therapeutic, has shown improved efficacy in preclinical models. Agonistic DR5 antibodies, such as TAS266 and INBRX-109, have also been developed, with INBRX-109 showing promising results in clinical trials for chondrosarcoma. Targeting p53 and mutant p53 is another important approach in cancer therapy. MDM2 inhibitors, such as APG-115, have shown promise in restoring p53 function. Eprenetapopt, a compound that reactivates mutant p53, has been studied in clinical trials for myelodysplastic syndromes and AML. KG13, an azaindole derivative, selectively targets mutant p53 and restores its function. Depletion of mutant p53 using compounds like ganetespib and SAHA has also been explored. The ISR is a conserved signaling pathway that can be activated by various stressors, including proteasome inhibitors. Activation of the ISR leads to the upregulation of proapoptotic genes, such as DR5, PUMA, and NOXA, which can induce apoptosis in cancer cells. Proteasome inhibitors like bortezomib and carfilzomib have been used in the treatment of multiple myeloma, but resistance mechanisms can develop. Dual inhibition of HDAC6 and the proteasome has shown promise in overcoming resistance. Overall, targeting apoptotic pathways, including intrinsic and extrinsic pathways, p53, and the ISR, represents a promising approach in cancer therapy. Continued research and development of drugs targeting these pathways may lead to more effective treatments for difficult-to-treat cancers.Apoptosis is a programmed cell death process that plays a critical role in development and homeostasis. Dysregulation of apoptosis is a hallmark of cancer, as cancer cells often evade apoptosis through various mechanisms. Targeting apoptotic pathways has been a major focus in cancer therapy, with efforts to develop drugs that induce apoptosis in cancer cells. Apoptosis can occur through intrinsic or extrinsic pathways, and these pathways interact with other signaling mechanisms such as p53 and the integrated stress response (ISR). Recent advances in cancer therapy include drugs targeting BCL-2, TRAIL analogs, DR5 antibodies, and strategies targeting p53 and the ISR. Venetoclax, a BCL-2 inhibitor, has been approved by the FDA for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). TRAIL analogs and DR5 agonist antibodies have also been developed, but their clinical efficacy has been limited due to issues such as short half-life and poor receptor clustering. TLY012, a second-generation TRAIL therapeutic, has shown improved efficacy in preclinical models. Agonistic DR5 antibodies, such as TAS266 and INBRX-109, have also been developed, with INBRX-109 showing promising results in clinical trials for chondrosarcoma. Targeting p53 and mutant p53 is another important approach in cancer therapy. MDM2 inhibitors, such as APG-115, have shown promise in restoring p53 function. Eprenetapopt, a compound that reactivates mutant p53, has been studied in clinical trials for myelodysplastic syndromes and AML. KG13, an azaindole derivative, selectively targets mutant p53 and restores its function. Depletion of mutant p53 using compounds like ganetespib and SAHA has also been explored. The ISR is a conserved signaling pathway that can be activated by various stressors, including proteasome inhibitors. Activation of the ISR leads to the upregulation of proapoptotic genes, such as DR5, PUMA, and NOXA, which can induce apoptosis in cancer cells. Proteasome inhibitors like bortezomib and carfilzomib have been used in the treatment of multiple myeloma, but resistance mechanisms can develop. Dual inhibition of HDAC6 and the proteasome has shown promise in overcoming resistance. Overall, targeting apoptotic pathways, including intrinsic and extrinsic pathways, p53, and the ISR, represents a promising approach in cancer therapy. Continued research and development of drugs targeting these pathways may lead to more effective treatments for difficult-to-treat cancers.